Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record.

Physiologically Based Pharmacokinetic Modeling: Science and Applications

·2005·Wiley eBooks

Abstract

Preface. Acknowledgments. Contributors. Chapter 1. Introduction: A Historical Perspective of the Development and Applications of PBPK Models. 1. Introduction. 2. A Historical Perspective. 2-1. Responses to Inhaled Compounds. 2-2. Pharmaceutical Applications. 2-3. Occupational and Environmental Applications. 2-4. Digital Computation and PBPK Modeling. 3. Expansion of PBPK Model Applications. 3-1. PBPK Models for Tissue Dosimetry from Secondary Data. 3-2. Biological Mechanisms Underlying PK Behaviors. 3-3. Chemicals as Probes of Biological Processes. 3-4. Risk Assessment Applications. 3-5. PBPK Models as Repository of Mechanistic Data on Distribution and Response. 4. Summary. PART I: PBPK MODELING FOR VOLATILE ORGANIC COMPOUNDS. Chapter 2. Halogenated Alkanes. 1. Introduction. 2. PBPK Model Development for Volatile Organics. 2-1. Model Formulation. 2-2. Model Equations. 2-3. Model Parameterization. 2-4. Model Calculations. 3. Advances in Experimental Methods Demonstrated for Groups of Chemicals. 4. PBPK Models for Halogenated Alkanes. 4-1. Anesthetic Gases. 4-2. Chlorofluorocarbons (CFCs), Refrigerants and Halons. 4-3. Halogenated Alkanes. 5. Summary. Chapter 3. Halogenated Alkenes. 1. Introduction. 2. The Chloroethylenes: Background. 3. Review of PBPK Models. 3-1. Vinyl Chloride (VC). 3-2. Vinyl Fluoride (VF). 3-3. cis-1,2-Dichloroethylene (cDCE) and trans-1,2-Dichloroethylene (tDCE). 3-4. Vinylidene Chloride (VDC). 3-5. Trichloroethylene (TCE). 3-6. Tetrachloroethylene (PERC). 3-7. Allyl Chloride (AC). 3-8. b-Chloroprene (CD). 3-9. Hexachlorobutadiene, HCB. 4. Summary. Chapter 4. Alkene and Aromatic Compounds. 1. Introduction. 2. PK and Pharmacodynamic Properties Important in PBPK Model Development for Aromatic and Alkene Compounds. 2-1. Metabolism and Mode of Action. 2-2. Model Structures. 2-3. PK Differences. 2-4. Extrahepatic Metabolism and Transport of Metabolites. 2-5. GSH Conjugation. 2-6. Endogenous Production. 2-7. Reactivity with DNA and Protein. 2-8. Inhibition of Second Oxidative Steps. 2-9. Variability and PK Differences. 2-10. Subcompartments in PBPK Models. 2-11. Privileged Access of Epoxide Hydratase to Epoxide Substrates. 3. Review of Aromatic and Alkene PBPK Models. 3-1. Benzene-A Known Human Carcinogen with an Uncertain Mode of Action. 3-2. Styrene- Early PBPK Models. 3-3. 1,3-Butadiene. 3-4. Isoprene. 3-5. Ethylene, Propylene and their Oxides. 3-6. Naphthalene and Other PAHs. 3-7. Halobenzenes. 3-8. Miscellaneous Related Compounds. 4. Summary. Chapter 5. Reactive Vapors in the Nasal Cavity. Introduction. 1-1. Nasal Effects and Risk Assessment. 1-2. General Models for Nasal Uptake. 1-2-1. Air Phase. 1-2-2. Specific Nasal Regions. 1-2-3. Air Phase Mass Transfer Coefficients. 1-2-4. Interfacial Mass Transfer Coefficient. 1-2-5. Tissue Diffusion. 2. No Air-Phase Models. 2-1. The Perfused Nose Model. 2-2. Vinyl Acetate. 3. Creating the Air Phase Compartments. 3-1. Computational Fluid Dynamics. 3-2. Estimating the Air Phase Mass Transfer Coefficient. 3-3. Estimating Air Phase Mass Transfer Coefficients - Acrylic Acid. 4. Other Models for Vapors Affecting Nasal Tissues. 4-1. Vinyl Acetate. 4-2. Ethyl Acrylate and its Metabolite, Acrylic Acid. 4-2. Epichlorohydrin. 5. Methyl Methacrylate. 6. Formaldehyde. 7. Hydrogen Sulfide. 10. Summary. Chapter 6. Alkanes, Oxyhydrocarbons, and Related Compounds. 1. Introduction. 2. Purposes for PBPK Model Development. 3. PBPK Models for Four Classes of Compounds. 3-1. Alkanes. 3-2. Oxyhydrocarbons. 3-3. Alkylbenzenes. 3-4. Siloxanes. 4. Summary. PARK II: PBPK MODEL DEVELOPMENT FOR ENVIRONMENTAL POLLUTANTS. Chapter 7. Pesticides and Persistent Organic Pollutants (POPs). 1. Introduction. 2. Pesticides. 2-1. Chemical Classes of Pesticides. 2-2. Modeling Tissue Distribution. 2-3. Modeling Metabolism. 2.4 Summary of Individual Models. 3. Polychlorinated and Polybrominated Biphenyls, PCBs and PBBs. 3-1. Modeling in Mammals. 3-2. Modeling in Nonmammalian Species. 4. Summary. Chapter 8. Dioxin and Related Compounds. 1. Introduction. 2. Toxicity. 3. Mode of Action. 4. Pharmacokinetics. 4-1. Absorption, Metabolism, and Excretion. 4-2. Distribution. 5. PBPK Models of TCDD. 5-1. PBPK Models of TCDD in Rodents. 5-2. PBPK Models of TCDD in Humans. 6. Summary. Chapter 9. Metals and Inorganic Compounds. 1. Introduction. 2. Physiologically Based Modeling of Metals. 2-1. Arsenic. 2-2. Nickel. 2-3. Lead. 2-4. Chromium. 3. PBPK Models for Non-Metals. 3-1. A PBPK Model for Fluoride, a Bone-Seeking Non-Metal. 3-2. PBPK Models for Other Non-Metals. 4. Compartmental Models for Miscellaneous Inorganic and/or Endogenous Chemicals. 5. Research Needs. 5-1. The Need for Physiologically Based Modeling for Essential Metals. 5-2. Other Research Needs. 6. Summary. PART III: PHARMACEUTICAL APPLICATIONS OF PBPK MODELS. Chapter 10. Drugs. 1. Introduction. 2. Describing the Tissue Distribution of Drugs. 3. Describing Metabolism and Other Clearance Processes of Drugs. 4. Other Issues in Model Devel

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/0471478768

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Venue
Wiley eBooks
Publisher
Wiley
Published
2005-01-27
OpenAlex
W599264250
Cited by
175
References
0
FWCI
8.58
Type
book
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Physiologically Based Pharmacokinetic Modeling: Science and Applications. https://app.cochat.ai/papers/10.1002/0471478768
The paper
Physiologically Based Pharmacokinetic Modeling: Science and Applications. (2005). Wiley eBooks. https://doi.org/10.1002/0471478768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.